{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T01:59:51Z","timestamp":1785635991101,"version":"3.56.0"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To investigate, in a pilot randomized controlled trial, whether etanercept (ETN) 25 mg once weekly is effective at maintaining a clinical response in patients with ankylosing spondylitis (AS) who have responded to the standard 50 mg dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Adults with AS not responding to conventional therapies were prescribed ETN 50 mg once weekly for 6 months. Responders as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were randomly assigned to taper to 25 mg once weekly or continue on 50 mg and followed for a further 6 months. The primary outcome measure was maintenance of a 50% reduction in the BASDAI or fall in BASDAI by \u2265 2 units and a \u2265 2-unit reduction in BASDAI spinal pain as measured on a 10-point visual analog scale at 6 months postrandomization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Of 89 patients assessed for eligibility, 59 were enrolled; 47 (80%) had sufficient clinical response and were eligible for randomization, 24 were assigned to continue receiving ETN 50 mg, and 23 to taper to 25 mg. After 6 months, 20 (83%) of the 50 mg arm maintained clinical response compared with 12 (52%) of the 25 mg arm (a difference of \u221231%, 95% CI \u221258% \u2013 \u22125%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Although this pilot study demonstrates that treatment with ETN 25 mg was less effective at maintaining treatment response in the stepdown phase, 52% of participants maintained treatment response. Future research should address which patients are suitable for tapering.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.141335","type":"journal-article","created":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T13:47:45Z","timestamp":1433252865000},"page":"1177-1185","source":"Crossref","is-referenced-by-count":51,"title":["Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial"],"prefix":"10.3899","volume":"42","author":[{"given":"Max","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise E.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Elender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Doll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joegi","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2015,6,1]]},"reference":[{"key":"2018112909342588000_42.7.1177.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780260210"},{"key":"2018112909342588000_42.7.1177.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70043-0"},{"key":"2018112909342588000_42.7.1177.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041129"},{"key":"2018112909342588000_42.7.1177.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.23275"},{"key":"2018112909342588000_42.7.1177.5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0132-y"},{"key":"2018112909342588000_42.7.1177.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.8.729"},{"key":"2018112909342588000_42.7.1177.7","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C"},{"key":"2018112909342588000_42.7.1177.8","first-page":"CD004524","article-title":"Methotrexate for ankylosing spondylitis","volume":"2","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909342588000_42.7.1177.9","first-page":"CD004800","article-title":"Sulfasalazine for ankylosing spondylitis","volume":"11","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909342588000_42.7.1177.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88269-7"},{"key":"2018112909342588000_42.7.1177.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"2018112909342588000_42.7.1177.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg135"},{"key":"2018112909342588000_42.7.1177.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61811-X"},{"key":"2018112909342588000_42.7.1177.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.03.010"},{"key":"2018112909342588000_42.7.1177.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel156"},{"key":"2018112909342588000_42.7.1177.16","first-page":"558","article-title":"Prospective observational analysis of the efficacy and safety of low-dose (3 mg\/kg) infliximab in ankylosing spondylitis: 4-year followup","volume":"33","author":"Keeling","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909342588000_42.7.1177.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091042"},{"key":"2018112909342588000_42.7.1177.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0674-2"},{"key":"2018112909342588000_42.7.1177.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1542-z"},{"key":"2018112909342588000_42.7.1177.20","doi-asserted-by":"crossref","first-page":"289845","DOI":"10.1155\/2013\/289845","article-title":"Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study","volume":"2013","author":"M\u00f6rck","year":"2013","journal-title":"Mediators Inflamm"},{"key":"2018112909342588000_42.7.1177.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1722-5"},{"key":"2018112909342588000_42.7.1177.22","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"2018112909342588000_42.7.1177.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1920-0"},{"key":"2018112909342588000_42.7.1177.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1549"},{"key":"2018112909342588000_42.7.1177.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem012"},{"key":"2018112909342588000_42.7.1177.26","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182514093"},{"key":"2018112909342588000_42.7.1177.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker083"},{"key":"2018112909342588000_42.7.1177.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2018112909342588000_42.7.1177.29","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909342588000_42.7.1177.30","unstructured":"National Institute for Health and Care Excellence . Adalimumab, etanercept and infliximab for ankylosing spondylitis. [Internet. Accessed April 22, 2015.] Available from: www.nice.org.uk\/guidance\/ta143"},{"key":"2018112909342588000_42.7.1177.31","unstructured":"European Medicines Agency . Enbrel. [Internet. Accessed April 22, 2015.] Available from: www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000262\/human_med_000764.jsp&mid=WC0b01ac058001d124"},{"key":"2018112909342588000_42.7.1177.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.141335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:58:47Z","timestamp":1543517927000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.141335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7,1]]},"published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.3899\/jrheum.141335"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.141335","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,1]]}}}